1. Home
  2. Labeler Index
  3. Csl Behring Ag
  4. 44206-455
  5. Product Images: Hizentra

Product Images Hizentra

View Photos of Packaging, Labels & Appearance

Table of Contents

  1. Figure 1 - hizentra 01
  2. Figure 2 - hizentra 02
  3. Figure 3 - hizentra 03
  4. Figure 4 - hizentra 04
  5. Figure 5 - hizentra 05
  6. Figure 6 - hizentra 06
  7. Figure 7 - hizentra 07
  8. Figure 8 - hizentra 08
  9. Figure 9 - hizentra 09
  10. Figure 10 - hizentra 10
  11. Figure 11 - hizentra 11
  12. Figure 12 - hizentra 12
  13. Figure 13 - hizentra 13
  14. Figure 14 - hizentra 14
  15. Figure 15 - hizentra 15
  16. Figure 16 - hizentra 16
  17. Figure 17 - hizentra 17
  18. Figure 18 - hizentra 18
  19. Figure 19 - hizentra 19
  20. Figure 1 - hizentra 20
  21. Figure 1 - hizentra 21
  22. Figure 2 - hizentra 22
  23. Figure 3 - hizentra 23
  24. Figure 4 - hizentra 24
  25. Figure 5 - hizentra 25
  26. Figure 6 - hizentra 26
  27. Figure 7 - hizentra 27
  28. Figure 8 - hizentra 28
  29. Figure 9 - hizentra 29
  30. Figure 10 - hizentra 30
  31. Figure 11 - hizentra 31
  32. Figure 12 - hizentra 32
  33. Figure 13 - hizentra 33
  34. Figure 14 - hizentra 34
  35. Figure 15 - hizentra 35
  36. Figure 16 - hizentra 36
  37. Figure 17 - hizentra 37
  38. Figure 18 - hizentra 38
  39. Figure 19 - hizentra 39
  40. PRINCIPAL DISPLAY PANEL - 5 mL Vial Carton - hizentra 40
  41. PRINCIPAL DISPLAY PANEL - 10 mL Vial Carton - hizentra 41
  42. PRINCIPAL DISPLAY PANEL - 20 mL Vial Carton - hizentra 42
  43. PRINCIPAL DISPLAY PANEL - 50 mL Vial Carton - hizentra 43
  44. PRINCIPAL DISPLAY PANEL - 5 mL Syringe Carton - hizentra 44
  45. PRINCIPAL DISPLAY PANEL - 10 mL Syringe Carton - hizentra 45
  46. PRINCIPAL DISPLAY PANEL - 20 mL Syringe Carton - hizentra 46

Product Label Images

The following 46 images provide visual information about the product associated with Hizentra NDC 44206-455 by Csl Behring Ag, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Figure 1 - hizentra 01

Figure 1 - hizentra 01

Figure 2 - hizentra 02

Figure 2 - hizentra 02

Figure 3 - hizentra 03

Figure 3 - hizentra 03

Figure 4 - hizentra 04

Figure 4 - hizentra 04

Figure 5 - hizentra 05

Figure 5 - hizentra 05

Figure 6 - hizentra 06

Figure 6 - hizentra 06

Figure 7 - hizentra 07

Figure 7 - hizentra 07

Figure 8 - hizentra 08

Figure 8 - hizentra 08

Figure 9 - hizentra 09

Figure 9 - hizentra 09

Figure 10 - hizentra 10

Figure 10 - hizentra 10

Figure 11 - hizentra 11

Figure 11 - hizentra 11

Figure 12 - hizentra 12

Figure 12 - hizentra 12

Figure 13 - hizentra 13

Figure 13 - hizentra 13

Figure 14 - hizentra 14

Figure 14 - hizentra 14

Figure 15 - hizentra 15

Figure 15 - hizentra 15

Figure 16 - hizentra 16

Figure 16 - hizentra 16

Figure 17 - hizentra 17

Figure 17 - hizentra 17

Figure 18 - hizentra 18

Figure 18 - hizentra 18

Figure 19 - hizentra 19

Figure 19 - hizentra 19

Figure 1 - hizentra 20

Figure 1 - hizentra 20

This appears to be a graph or chart with data points and labels on it. The graph shows some numbers and percentages related to a study, possibly on two different dosages of a medication (0.2 g/kg and 0.4 g/kg of Hizentra) versus a placebo. The numbers may refer to the probability of relapse or withdrawal for each treatment group over a period of time. Without more context or information, it is difficult to provide a full and accurate description of the data.*

Figure 1 - hizentra 21

Figure 1 - hizentra 21

Figure 2 - hizentra 22

Figure 2 - hizentra 22

Figure 3 - hizentra 23

Figure 3 - hizentra 23

Figure 4 - hizentra 24

Figure 4 - hizentra 24

Figure 5 - hizentra 25

Figure 5 - hizentra 25

Figure 6 - hizentra 26

Figure 6 - hizentra 26

Figure 7 - hizentra 27

Figure 7 - hizentra 27

Figure 8 - hizentra 28

Figure 8 - hizentra 28

Figure 9 - hizentra 29

Figure 9 - hizentra 29

Figure 10 - hizentra 30

Figure 10 - hizentra 30

Figure 11 - hizentra 31

Figure 11 - hizentra 31

Figure 12 - hizentra 32

Figure 12 - hizentra 32

Figure 13 - hizentra 33

Figure 13 - hizentra 33

Figure 14 - hizentra 34

Figure 14 - hizentra 34

Figure 15 - hizentra 35

Figure 15 - hizentra 35

Figure 16 - hizentra 36

Figure 16 - hizentra 36

Figure 17 - hizentra 37

Figure 17 - hizentra 37

Figure 18 - hizentra 38

Figure 18 - hizentra 38

Figure 19 - hizentra 39

Figure 19 - hizentra 39

PRINCIPAL DISPLAY PANEL - 5 mL Vial Carton - hizentra 40

PRINCIPAL DISPLAY PANEL - 5 mL Vial Carton - hizentra 40

This package contains a single-dose vial of Hizentra® immune globulin subcutaneous (human), which is a 20% liquid solution of human immunoglobulin. The complete directions for use, dosage information, and product compatibility are enclosed in the package insert. There is no preservative present in the solution. It is made from human plasma that may contain infectious agents and viruses, including the causative agent of Creutzfeldt-Jakob disease (CJD). The package insert lists all warnings and precautions associated with the use of Hizentra®. Storage of the product should be at room temperature up to 25°C (77°F) and kept in the original carton. There is a confidential industry program available and distributed by CSL Behring LLC.*

PRINCIPAL DISPLAY PANEL - 10 mL Vial Carton - hizentra 41

PRINCIPAL DISPLAY PANEL - 10 mL Vial Carton - hizentra 41

This is a product description of a 10 mL solution of Immune Globulin Subcutaneous (Human) with complete directions for use contained in the package which also includes single-dose vials. This human plasma-derived product contains no preservative and is 20% liquid. The product may cause CID (Creutzfeldt-Jakob disease) in rare instances and there is a warning and precautions section in the package insert for further information. The product should be stored at room temperature and the expiration date printed on the carton and label should be followed as well as protecting it from light. Any unused or expired product should be discarded along with used disposable supplies. There is a Patient Notification System available with a call to the manufacturer. The product is manufactured and distributed by CSLBehring.*

PRINCIPAL DISPLAY PANEL - 20 mL Vial Carton - hizentra 42

PRINCIPAL DISPLAY PANEL - 20 mL Vial Carton - hizentra 42

This package appears to contain a medication called "Immune Globulin" in single-dose vials. The solution inside the vial is stable at room temperature for a period indicated by the expiration date. It is meant for subcutaneous administration. The package has directions for use and dosage information. There is also a phone number to enroll in a patient notification system.*

PRINCIPAL DISPLAY PANEL - 50 mL Vial Carton - hizentra 43

PRINCIPAL DISPLAY PANEL - 50 mL Vial Carton - hizentra 43

This is a description of CSL Behring's Hizentra - a single-dose subcutaneous Immunoglobulin (Human) containing 10g human immune globulin in 50L solution. The storage guidelines indicate that it should be stored at room temperature until the expiration date printed on the carton and the vial label. The package insert should be followed for usage directions, dosage information, and product compatibility. It is also noted that products made from human plasma may contain infectious agents such as viruses, theoretically causing diseases such as Creutzfeld-Jakob disease (CJD). Hence, a warning is given to refer to the package insert's Warnings and Precautions section.*

PRINCIPAL DISPLAY PANEL - 5 mL Syringe Carton - hizentra 44

PRINCIPAL DISPLAY PANEL - 5 mL Syringe Carton - hizentra 44

PRINCIPAL DISPLAY PANEL - 10 mL Syringe Carton - hizentra 45

PRINCIPAL DISPLAY PANEL - 10 mL Syringe Carton - hizentra 45

The text contains some unreadable characters, no human understandable text is available.*

PRINCIPAL DISPLAY PANEL - 20 mL Syringe Carton - hizentra 46

PRINCIPAL DISPLAY PANEL - 20 mL Syringe Carton - hizentra 46

This appears to be a medical description with the mentions of various drugs and their administration. The text also includes details about Immune Globulin Subcutaneous, 20% Liquid.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.